PTO/SB/08A					Complete if Known		
IN	RMATION	DISCL	OSUR	RE	Application Number	09/637,962	
	ATEMENT B				Filing Date	August 11, 2000	
101	PE	D	トしに		Confirmation Number	8001	
	CIE		und t	A 5003	First Named Inventor	Lawrence H. Thompson	
MAR 1	2 2003		MAN	ITER 1600	oup Art Unit	1647	
PATERIA TA	DEMARKE	TE	Chi UEN	AI CITTO	Examiner Name	Regina M. Deberry	
Sheet	1	of		5	Attorney Docket No.	500731.01 (BXTD 9005)	

			NS	PATEN	T DOCUMENTS		
			U.S. Patent Docume		J	;	
Examiner Initials*	Cite No. ¹	Number		Kind Code ² (if) kylown)	Name of Patentee or Applicant of Cited Document	Date of Publication of C Document MM-DD-YYYY	
	1	4,703,0	08		Jin/F-K	10/27/1987	
	2	5,688,6	79		Powgii, J.S.	11/18/1997	
	3	5,955,4	22		Lip/F-K	09/21/1999	
	4	2002/0	037832	A1	Nielsen et al.	03/28/2002	
			FOREI	GN PATE	ENT DOCUMENTS		
		F	oreign Patent Docur	nent			
Examiner Initials*	Cite No.1	Office	Number ⁴	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
	5	EP	0 813 877	A2	SmithKline Beecham Corporation	12/29/1997	
	6	wo	88/00241	A1	Board of Regents of the University of Washington	01/14/1988	
	7	wo	00/24893	A2	AMGEN Inc.	05/04/2000	
	8	wo	00/35475	A2	Ehrenreich, Hannelore	00/22/2000	
 	9	wo	01/82952	A2	Action Pharmaceuticals APS	11/08/2001	

			· · · · · · · · · · · · · · · · · · ·	
Examiner	0	Date		\
Signature	C	Considered		\

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an ⁴A* here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

parper no: 14

PTO/SB/08A	Complete if Known			
INFORMATION DISCLOSURE	Application Number	09/637,962		
STATEMENT BY APPLICANT	Filing Date	August 11, 2000		
OIPE	Confirmation Number	8001		
	First Named Inventor	Lawrence H. Thompson		
ابن MAR 1 2 2003	Group Art Unit	1647		
RADEMARK.	Examiner Name	Regina M. Deberry		
Sheet 2 of 5	Attorney Docket No.	500731.01 (BXTD 9005)		

<u> </u>	T.,	1,440	101/01700		Τ.,	Tou Marine	10/00/0004	Т	
	10	wo	01/91780	/-	A1	Ortho-McNeil Pharmaceutical, Inc.	12/06/2001	<u> </u>	
		OTH	IER ART - N	ON	PATEN	T LITERATURE DOCUMEN	TS :		
Examiner Initials*	Cite No.1		m (book, magazi	ne, j	ournai, ser	AL LETTERS), title of the article (when ial, symposium, catalog, etc.) date, parher, city and/or country where published	ge(s), volume-issue	T _e	
	11 _	Anaem				ecombinant Human Omega Erythropoi , Journal of the Association of Physicia			
	12 /		A, D.H., Erythrop of Medicine, (19			nt for Non-Uremic Patients: A Persona Vol. 54	l View, The Netherlands		
	13 /	BIESM/ Treatm	A, D.H. et al., Lov ent with Recomb	ver l	Homologou t Human Ei	s Blood Requirement in Autologous Bl rythropoletin, The Lancet, (1994), pp. 3	ood Donors After 367-370, Vol. 344		
	14	Anemia	BREN, A. et al., A Comparison Between Epoetin mega and Epoetin Alfa in the Correction of Anemia in Hemodialysis Patients: A Prospective, Controlled Crossover Study, Artificial Organs, (2002), pp. 91-97, Vol. 26:2						
	15_/	BREN, Soc Ne	BREN, A.F. et al., Experiences with Epoetin Omega and Epoetin Alfa in Hemodialysis Patients, J Am Soc Nephrol, A1813, (2001), p. 352A, Vol. 12						
	16	Erythro	CANADIAN ERYTHROPOIETIN STUDY GROUP, Association Between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis, BMJ, (1990), pp. 573-578, Vol. 300						
	17 -					rythropoietin Antibodies in Haemodial n, Pharmacological Research, (2000),			
	18		CHOI, D. et al., Erythropoietin: Physico- and Biochemical Analysis, Journal of Chromatography B: BioMedical Applications, (1996), Abstract						
	19	CUMMINGS, M.N. et al., Subcutaneous Erythropoietin Alpha (Eprex) is More Painful Than Erythropoietin Beta (Recormon), Nephrol Dial Transplant, (1998), p. 817, Vo. 13							

Examiner	Date	
Signature	Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English Language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Raper No: 14

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/	08A		•	Comple	ete if Known
IN	FORMATION	DISCL	OSURE	Application Number	09/637,962
ST	TATEMENT B	Y APPI	LICANT	Filing Date	August 11, 2000
0	PERE			Confirmation Number	8001
MAR	1 2 2003			First Named Inventor	Lawrence H. Thompson
PARTE	PADEMARY C.F.			Group Art Unit	1647
81	RADEMAR			Examiner Name	Regina M. Deberry
Sheet	3.	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

20	.0	FARIS, P.M. et al., The Effects of Recombinant Human Erythropoietin on Perioperative Transfusion Requirements in Patients Having a Major Orthopaedic Operation, The Journal of Bone and Joint Surgery, (1996), pp. 62-72, Vol. 78-A:1
2	11 /	FAULDS, D. et al. Epoetin (Recombinant Human Erythropoietin) A Review of its Pharmacodynamic and Pharmacokine ic Properties and Therapeutic Potential in Anaemia and the Stimulation of Erythropoiesis, Drugs (1989), pp. 863-899, Vol. 38:6
2:	2 /	FRENKEN, L.A.M. et al., Assessment of Pain After Subcutaneous Injection of Erythropoietin in Patients Receiving Haemodialysis, BMJ, (1991), p. 288, Vol. 303
23	3 /	FULTON, B. et al., Mycophenolate Mofetil - A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation, Drugs, (1996), pp. 278-298, Vol. 51:2
24	4	HALSTENSON, C.E. et al. Comparative Pharmacokinetics and Pharmacodynamics of Epoetin Alfa and Epoetin Beta, Clin Pharmacol Ther, (1991), pp. 702-712, Vol. 50
25	5 /	HENDRIKS, M.W.G. et al., Is Recormon® Less Painful Than Eprex® After Subcutaneous Administration?, Pharmaceutisch Weel plad Scientific Edition, (1992), pp. 55-58, Vol. 14:2
26	6 -	LUDWIG, H., Epoetin in Cancer-Related Anaemia, Nephrol Dial Transplant, (1999), pp. 85-92, Vol. 14:2
27	7	MACDOUGALL, I.C. et al., Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients, J Am Soc Nephrol, (1999), pp. 2392-2395, Vol. 10
28	8 /	MARKHAM, A. et al., Epoetin Alfa - A Review of its Pharmacodynamic and Pharmocokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, pp. 232-254, Vol 49:2
29	9 / +	MILUTINOVIC, S. et al., Chronic Renal Failure: Anaemia, Enythropsietin-Induced Hypertension in Dialyzed Uremics is Influenced by Glycosylation Patterns of the Molecule; Nephrology Dialysis Transplantation, (2001), p. A91, Vol. 16:6, Abstract
30	0 -	MILUTINOVIC, S. et al., Dialysis: Anaemia and Erythropoietin Treatment, Differences in Glycosylation Structures Have an Important Impact on Potency and Pharmacokinetics of Erythropoietin (EPO) in Dialyzed Uremics, Nephrology Dialysis Transplantation, (2000), p. A156, Vol. 15:9, Abstract

Examiner		Date		
Signature	1 W .	Considered	\	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

perler Mily

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

PTO/SB	/08A	,	•	Comple	ete if Known
IN	FORMATION I	DISCL	.OSURE	Application Number	09/637,962
S	TATEMENT BY	APP	LICANT	Filing Date	August 11, 2000
	SIPE			Confirmation Number	8001
MA	R 1 2 2003			First Named Inventor	Lawrence H. Thompson
PARTE	2000			Group Art Unit	1647
TRADEMARK CO.				Examiner Name	Regina M. Deberry
Sheet	4	9(5	Attorney Docket No.	500731.01 (BXTD 9005)

			\						
	31	1	MILUTINOVIC, S. et al., Dialysis: Complications of Hemodialysis, Efficacy and Pharmacokinetics of Human Erythropoietins in Dialyzed Uremic Patients Depend on Glycosylation Pattern of the Molecule, J Am Soc Nephiol, A1512, (2000), p. 289A, Vol. 11						
	32	1	MILUTINOVIC, S. et al., Erythropoietin (E Life in Dialysis Patients in Comparison to	PO) Omega Impr ALFA, J Am Soc	oves Cognitive Functioning and Quality of Nephrol, (2002), p. 718A, Vol. 13, Abstract				
	33	/	MILUTINOVIC, S. et al, Once Weekly Er Twice Weekly Regimen in cornecting Ane Transplantation, M315, (2002), p. 136, Vo	mia of Dialyzed P					
	34		MIYAKE, T. et al., Purification of Humanni pp. 5558-5564, Vol. 252:15	Erythropoletin, The	e Journal of Biological Chemistry, (1977),				
	35		Containing Oligomannosidic N-Glycan fro	NIMITZ, M. et al., Identification and Structural Characterization of a Mannose-6-Phosphate Containing Oligomannosidic N-Glycan from Hurrian Erythropoietin Secreted by Recombinant BHK-21 Cells, FEBS Letters, (1995), pp. 203-208, Vol. 865					
	36	/	NIMTZ, M. et al., Structures of Sialylated Recombinant BHK-21 Cells, Eru. J. Bioch	NIMTZ, M. et al., Structures of Sialylated Oligosacoparides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells, Eru. J. Biochem., (1993), pp. 39-56, Vol. 213					
	37	/	PECES, R. et al., Antibodies Against Rec Erythropoietin-Resistant Anemia, The Nev Vol. 335:7	ombinant Human w England Journa	Erythropoietin in a Patient with of Medicine, (1996), pp. 523-524,				
	38	,	SANS, T. et al., Effectiveness of Very Lov Erythropoietin in Facilitating Autologous E (1996), pp. 822-826, Vo. 36:9	v Doses of Subcut Blood Donation Be	taneous Recombinant Human fore Orthopedic Surgery, Transfusion,				
	39	_	SIKOLE, A. et al., Epoetin Omega for Tre- Clinical Nephrology, pp. 237-245, Vol. 57	atment of Anemia	in Maintenance Hemodialysis Patients,				
	40	/		STORRING, P.L. et al., Epoetin Alfa and Beta Differ in Their Erythropoietin Isoform Compositions and Biological Properties, British Journal of Haematology, (1998), pp. 79-89, Vol. 100					
	41	¥	SYTKOWSKI, A.J. et al., Biological Activity and Structural Stability of N-Deglycosylated Recombinant Human Erythropoietin, Biochemical and Biophysical Research Communications, (1991), pp. 698-704, Vol. 176:2						
Examiner Signature				Date Considered					

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper ND: 14

PTO/SE	B/08A		•	Comple	Complete if Known		
	NFORMATION I	DISC	CLOSURE	Application Number	09/637,962		
8	STATEMENT BY	/ AP	PLICANT	Filing Date	August 11, 2000		
	OIPE			Confirmation Number	8001		
/	MAD 1 3 2000			First Named Inventor	Lawrence H. Thompson		
(MAR 1 2 2003			Group Art Unit	1647		
	TRADEMARK CO.	\		Examiner Name	Regina M. Deberry		
Sheet	5	of	5	Attorney Docket No.	500731.01 (BXTD 9005)		

42		et al., The Role of Carbohydrate in Recombinant Human Erythropoietin, Eur. J. Biochem., 405,411, Vol. 188
43	Phosphate	et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin: -Buffered Epoetin Alpha Compared to Citrate-Buffered Epoetin Alpha and Epoetin Beta, -phrology (1998), pp. 41-44, Vol. 49:1
44	Maintenan	et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin in ce Hemodialysis Patients: A Comparison of Two Brands of Erythropoietin, Am J Nephrol, 68-72, Vol. 1258

		<u> </u>	
Examiner	Date		
Signature	Considered	\\	

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper NO:14

PTO/SB/08A			Complete	e if Known
INFORMATIO	ON DISC	LOSURE	Application Number	09/637,962
STATEMENT	BY AP	PLICANT	Filing Date	August 11, 2000
	-	RECEIVED	Confirmation Number	8001
OIPE	٨	MAR 1 % 2003	First Named Inventor	Lawrence H. Thompson
MAR 0 7 2003 %	TECH	CENTER 1600/2900	Group Art Unit	1647
	I EOI I	OLIVIER 1000/2900	Examiner Name	Regina M. Deberry
Sheet 1	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

			U.	S. PAT	ENT	DOCUMENTS		
			U.S. Patent Docu	ıment				
Examiner Initials*			Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of C Document MM-DD-YYYY	Cited	
Jour	1	4,703,0	08			Lin, F-K	10/27/1987	
	2	5,688,6	79			Powell, J.S.	11/18/1997	
11.0	3	5,955,4	5,955,422			Lin, F-K	09/21/1999	
740	4	2002/0037832 A				Nielsen et al.	03/28/2002	
-			FOR	EIGN F	ATE	ENT DOCUMENTS		
		F	oreign Patent Do	cument				
Examiner Initials*	Cite No.1	Office	Number⁴	Kind Cod (if kno		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
WW)	5	EP	0 813 877	A2		SmithKline Beecham Corporation	12/29/1997	
	6	wo	88/00241	A1		Board of Regents of the University of Washington	01/14/1988	
	7	wo	00/24893	A2		AMGEN Inc.	05/04/2000	
10	8	wo	00/35475	A2		Ehrenreich, Hannelore	06/22/2000	
TKN)	9	wo	01/82952	A2		Action Pharmaceuticals APS	11/08/2001	

Examiner Signature Date Considered 6 2 3	 	~ 10		1)
		\mathcal{A}	i i	6	121	153

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

ROYPELNO: 14

PTO/SB/08A			Complete if Known		
INFORMATION	ON DISC	LOSURE	Application Number	09/637,962	
STATEMEN	T BY AP	PLICANT	Filing Date	August 11, 2000	
RECEIVED		ECEIVED	Confirmation Number	8001	
	O I P E NA		First Named Inventor	Lawrence H. Thompson	
MAR 0 7 2003		AR 1 2 2003	Group Art Unit	1647	
	IECH (CENTER 1600/2900	Examiner Name	Regina M. Deberry	
Sh et 2	of	5	Attorney Docket No.	500731.01 (BXTD 9005)	

· My	10	wo	01/91780	A1	Ortho-McNeil Pharmaceutical, Inc.	12/06/2001	1			
OTHER ART - NON PATENT LITERATURE DOCUMENTS										
Examiner Initials*	Tem monk manazine infilmati seliat symbosium, catalog, etc., gate, pagets), volume issue									
10	ACHARYA et al., Effect of Low Dose Recombinant Human Omega Erythropoietin (rHuEPO) on Anaemia in Patients with Hemodialysis, Journal of the Association of Physicians of India, (1995), pp. 539-542, Vol. 43:8									
	BIESMA, D.H., Erythropoietin Treatment for Non-Uremic Patients: A Personal View, The Netherlands Journal of Medicine, (1999), pp. 10-15, Vol. 54									
	BIESMA, D.H. et al., Lower Homologous Blood Requirement in Autologous Blood Donors After Treatment with Recombinant Human Erythropoietin, The Lancet, (1994), pp. 367-370, Vol. 344									
	14	BREN, A. et al., A Comparison Between Epoetin Omega and Epoetin Alfa in the Correction of Anemia in Hemodialysis Patients: A Prospective, Controlled Crossover Study, Artificial Organs, (2002), pp. 91-97, Vol. 26:2								
	15	BREN, Soc Ne	A.F. et al., Experience ephrol, A1813, (2001)	es with Epo p. 352A, V	oetin Omega and Epoetin Alfa in Hemo /ol. 12	odialysis Patients, J Am				
	CANADIAN ERYTHROPOIETIN STUDY GROUP, Association Between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis, BMJ, (1990), pp. 573-578, Vol. 300									
	17	CASTE with Re	ELLI, G. et al., Detecti ecombinant Human-E	on of Anti-E rythropoieti	Erythropoietin Antibodies in Haemodial n, Pharmacological Research, (2000),	ysis Patients Treated pp. 313-318, Vol. 41:3				
	18	CHOI, BioMed	D. et al., Erythropoiet dical Applications, (19	in: Physico 96), Abstra	- and Biochemical Analysis, Journal o	f Chromatography B:				
My.	19	CUMM Erythro	IINGS, M.N. et al., Su ppoietin Beta (Recorm	bcutaneous ion), Nephr	s Erythropoietin Alpha (Eprex) Is More ol Dial Transplant, (1998), p. 817, Vol	Painful Than 13				

•			
Examiner Signature	KMOeky	Date Considered	11213

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/	08A			Comple	te if Known
INI	FORMATION	DISC	LOSURE	Application Number	09/637,962
	ATEMENT B	Y AP	PLICANT	Filing Date	August 11, 2000
	OIPE	ı	RECEIVED	Confirmation Number	8001
1	AR 0 7 2003 (S)		MAR 1 2 2003	First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
. 🗞	MADEMAN	.=0[]	OENTER 1600/2900	Group Art Unit Examiner Name	Regina M. Deberry
Sheet	3	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

		_			
20	FARIS, P.M. et al., The Effects of Recombinant Human Erythropoietin on Perioperative Transfusion Requirements in Patients Having a Major Orthopaedic Operation, The Journal of Bone and Joint Surgery, (1996), pp. 62-72, Vol. 78-A:1	1			
21	FAULDS, D. et al., Epoetin (Recombinant Human Erythropoietin) A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Anaemia and the Stimulation of Erythropoiesis, Drugs, (1989), pp. 863-899, Vol. 38:6				
22	FRENKEN, L.A.M. et al., Assessment of Pain After Subcutaneous Injection of Erythropoietin in Patients Receiving Haemodialysis, BMJ, (1991), p. 288, Vol. 303				
23	FULTON, B. et al., Mycophenolate Mofetil - A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation, Drugs, (1996), pp. 278-298, Vol. 51:2				
HALSTENSON, C.E. et al., Comparative Pharmacokinetics and Pharmacodynamics of Epoetin Alfa and Epoetin Beta, Clin Pharmacol Ther, (1991), pp. 702-712, Vol. 50					
25	HENDRIKS, M.W.G. et al., Is Recormon® Less Painful Than Eprex® After Subcutaneous Administration?, Pharmaceutisch Weekblad Scientific Edition, (1992), pp. 55-58, Vol. 14:2				
26	LUDWIG, H., Epoetin in Cancer-Related Anaemia, Nephrol Dial Transplant, (1999), pp. 85-92, Vol. 14:2				
27	MACDOUGALL, I.C. et al., Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients, J Am Soc Nephrol, (1999), pp. 2392-2395, Vol. 10				
28	MARKHAM, A. et al., Epoetin Alfa - A Review of its Pharmacodynamic and Pharmocokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, pp. 232-254, Vol 49:2				
29	MILUTINOVIC, S. et al., Chronic Renal Failure: Anaemia, Erythropoietin-Induced Hypertension in Dialyzed Uremics is Influenced by Glycosylation Patterns of the Molecule, Nephrology Dialysis Transplantation, (2001), p. A91, Vol. 16:6, Abstract				
30	MILUTINOVIC, S. et al., Dialysis: Anaemia and Erythropoietin Treatment, Differences in Glycosylation Structures Have an Important Impact on Potency and Pharmacokinetics of Erythropoietin (EPO) in Dialyzed Uremics, Nephrology Dialysis Transplantation, (2000), p. A156, Vol. 15:9, Abstract				
	21 22 23 24 25 26 27 28 29	Requirements in Patients Having a Major Orthopaedic Operation, The Journal of Bone and Joint Surgery, (1996), pp. 62-72, Vol. 78-A:1 FAULDS, D. et al., Epoetin (Recombinant Human Erythropoietin) A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Anaemia and the Stimulation of Erythropoiesis, Drugs, (1989), pp. 863-899, Vol. 38:6 FRENKEN, L.A.M. et al., Assessment of Pain After Subcutaneous Injection of Erythropoietin in Patients Receiving Haemodialysis, BMJ, (1991), p. 288, Vol. 303 FULTON, B. et al., Mycophenolate Mofetil - A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation, Drugs, (1996), pp. 278-298, Vol. 51:2 HALSTENSON, C.E. et al., Comparative Pharmacokinetics and Pharmacodynamics of Epoetin Alfa and Epoetin Beta, Clin Pharmacol Ther, (1991), pp. 702-712, Vol. 50 HENDRIKS, M.W.G. et al., Is Recormon® Less Painful Than Eprex® After Subcutaneous Administration?, Pharmaceutisch Weekblad Scientific Edition, (1992), pp. 55-58, Vol. 14:2 LUDWIG, H., Epoetin in Cancer-Related Anaemia, Nephrol Dial Transplant, (1999), pp. 85-92, Vol. 14:2 MACDOUGALL, I.C. et al., Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients, J Am Soc Nephrol, (1999), pp. 2392-2395, Vol. 10 MARKHAM, A. et al., Epoetin Alfa - A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, pp. 232-254, Vol 49:2 MILUTINOVIC, S. et al., Chronic Renal Failure: Anaemia, Erythropoietin-Induced Hypertension in Dialyzed Uremics is Influenced by Glycosylation Patterns of the Molecule, Nephrology Dialysis Transplantation, (2001), p. A91, Vol. 16:6, Abstract MILUTINOVIC, S. et al., Dialysis: Anaemia and Erythropoietin Treatment, Differences in Glycosylation Structures Have an Important Impact on Potency and Pharmacokinetics of Erythropoietin (EPO) in Dialyzed Uremics, Nephrology Dialysis Transplantation, (2000), p. A156,			

	<i>I</i>		1_	\sim			<u> </u>		
Examiner Signature	R	M	7. / 1 /	3A)	Date Considered	61	12	15)

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/0)8A			Comple	te if Known
INF	ORMATION	DISC	LOSURE	Application Number	09/637,962
	ATEMENT B			Filing Date	August 11, 2000
	OIPE		RECEIVE	Confirmation Number	8001
1	MAR 0 7 2003 2		MAD -	Confirmation Number Pirst Named Inventor	Lawrence H. Thompson
	, J.		. (111) 4	I Croup Art I Init	1647
TADHMAN!		IE(H CENTER 1600/20	Examiner Name	Regina M. Deberry
Sheet	4	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

è							
PM	31	MILUTINOVIC, S. et al., Dialysis: Complications of Hemodialysis, Efficacy and Pharmacokinetics of Human Erythropoietins in Dialyzed Uremic Patients Depend on Glycosylation Pattern of the Molecule, J Am Soc Nephrol, A1512, (2000), p. 289A, Vol. 11					
	32	MILUTINOVIC, S. et al., Erythropoietin (EPO) Omega Improves Cognitive Functioning and Quality of Life in Dialysis Patients in Comparison to ALFA, J Am Soc Nephrol, (2002), p. 718A, Vol. 13, Abstract					
	33	MILUTINOVIC, S. et al., Once Weekly Erythropoietin Omega Treatment is Safe and as Effective as Twice Weekly Regimen in correcting Anemia of Dialyzed Patients, Nephrology Dialysis Transplantation, M315, (2002), p. 136, Vol. 17, Abstract					
	34	MIYAKE, T. et al., Purification of Human Erythropoietin, The Journal of Biological Chemistry, (1977), pp. 5558-5564, Vol. 252:15					
	35	NIMITZ, M. et al., Identification and Structural Characterization of a Mannose-6-Phosphate Containing Oligomannosidic <i>N</i> -Glycan from Human Erythropoietin Secreted by Recombinant BHK-21 Cells, FEBS Letters, (1995), pp. 203-208, Vol. 365					
	36	NIMTZ, M. et al., Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells, Eru. J. Biochem., (1993), pp. 39-56, Vol. 213					
	37	PECES, R. et al., Antibodies Against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant Anemia, The New England Journal of Medicine, (1996), pp. 523-524, Vol. 335:7					
	38	SANS, T. et al., Effectiveness of Very Low Doses of Subcutaneous Recombinant Human Erythropoietin in Facilitating Autologous Blood Donation Before Orthopedic Surgery, Transfusion, (1996), pp. 822-826, Vo. 36:9					
	39	SIKOLE, A. et al., Epoetin Omega for Treatment of Anemia in Maintenance Hemodialysis Patients, Clinical Nephrology, pp. 237-245, Vol. 57					
	40	STORRING, P.L. et al., Epoetin Alfa and Beta Differ in Their Erythropoietin Isoform Compositions and Biological Properties, British Journal of Haematology, (1998), pp. 79-89, Vol. 100					
Rin	41	SYTKOWSKI, A.J. et al., Biological Activity and Structural Stability of N-Deglycosylated Recombinant Human Erythropoietin, Biochemical and Biophysical Research Communications, (1991), pp. 698-704, Vol. 176:2					
Examiner Signature	K	MINDER Date Considered (1) 13					

Signature Considered Considered

*EXAMINER: Initial if reference considered, whether or not citation is no conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known		
INFORMATION DISCLOSURE				Application Number	09/637,962	
STATEMENT BY APPLICANT				Filing Date	August 11, 2000	
OIPE		RECEIVED		Confirmation Number	8001	
	0 7 2000 55	MAR 1 2 2003		First Named Inventor	Lawrence H. Thompson	
	Ĕ.			Group Art Unit	1647	
TECH CENTER 1600/2900			CENTER 1600/2900	Examiner Name	Regina M. Deberry	
Sheet	5	of	5	Attorney Docket No.	500731.01 (BXTD 9005)	

K	W)	42	TSUDA, E. et al., The Role of Carbohydrate in Recombinant Human Erythropoietin, Eur. J. Biochem., (1990), pp. 405-411, Vol. 188	
		43	VEYS, N. et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin: Phosphate-Buffered Epoetin Alpha Compared to Citrate-Buffered Epoetin Alpha and Epoetin Beta, Clinical Nephrology, (1998), pp. 41-44, Vol. 49:1	
AM.		44	VEYS, N. et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin in Maintenance Hemodialysis Patients: A Comparison of Two Brands of Erythropoietin, Am J Nephrol, (1992), pp. 68-72, Vol. 12:68	

	Λ	•	1					
Examiner Signature	MY		181	Date Considered	6	12	DP.	
			דיע		i		Θ	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

POYPEL NO: 14